CIAM
CRNX icon

Caitong International Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Caitong International Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.3K Buy
+1,660
New +$74.1K 0.01% 727
2025
Q3 		– Sell
-1
Closed -$29 – 2042
2025
Q2 		$29 Buy
+1
New +$31 ﹤0.01% 1887

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Caitong International Asset Management's CRNX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 1,660 shares worth $60.3K. The stake represents 0.01% of the portfolio and ranks #727 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in CRNX as recently as Q2 2025.

Caitong International Asset Management first reported a position in CRNX in Q2 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Caitong International Asset Management held 1,660 shares of Crinetics Pharmaceuticals worth $60.3K as of Q1 2026.
  • Crinetics Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
  • Crinetics Pharmaceuticals made up 0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #727 holding.
  • Caitong International Asset Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.